Many governments, including the U.S. and Japan, are well aware of the dangers to their populations of exposure to high levels of radiation from nuclear accidents or dirty bomb attacks. Whereas Japan’s population was recently exposed at Fukushima following the tsunami of 2011, the U.S. Department of Defense has been stockpiling acute radiation syndrome (ARS) countermeasures as a precaution for many years. [Read more…]
PLX-R18 Supports Hematological Recovery After Low Radiation Exposure
-
Findings pave the way to potentially use PLX-R18 to support hematological recovery following radiotherapy or chemotherapy
-
Data focuses on 12 additional NHPs that were exposed to lower radiation levels
HAIFA, ISRAEL, JULY 26, 2017— Pluristem Therapeutics Inc. (NASDAQ: PSTI) (TASE: PSTI), a leading developer of placenta-based cell therapy products, today presented new data at the RITN (Radiation Injury Treatment Network) conference from a recent study evaluating PLX-R18 as a treatment for Acute Radiation Syndrome (ARS). [Read more…]
Dr. Kleinhaus of Pluristem Therapeutics on Immune-Advantaged Placental-Derived PLX-Cells
Pluristem Therapeutics is a clinical-stage biotherapy company using placental cells and an advanced 3D manufacturing platform to develop cell therapies for conditions that include inflammation, ischemia, muscle trauma, hematological disorders, or exposure to radiation. Their two lead cell products are entering late-stage clinical trials. Based in Haifa, Israel, Pluristem’s propriety bioreactor technology provides full-scale cell manufacturing capabilities that allow it to expand trillions of cells and create a commercial-grade product. [Read more…]
Pluristem Announces Promising Results from Non-Human Primate Pilot Study of PLX-R18 in Acute Radiation Syndrome
- All PLX-treated groups showed improvements in survival rates compared to untreated groups
- PLX-R18 cells did not increase leukocyte levels in non-irradiated NHPs, indicating no requirement to determine levels of radiation exposure prior to administration
- Data will inform a pivotal trial that could support marketing authorization under the FDA’s Animal Rule regulatory pathway
Governments on Alert and Stockpiling Antidotes for Nuclear Accidents and Attacks
Many governments, including the U.S. and Japan, are well aware of the dangers to their populations of exposure to high levels of radiation from nuclear accidents or dirty bomb attacks. Whereas Japan’s population was recently exposed at Fukushima following the tsunami of 2011, the U.S. Department of Defense has been stockpiling acute radiation syndrome (ARS) countermeasures as a precaution for many years.
The recent escalation of tensions between North Korea and the U.S. may give the American government cause to up its investment in ARS antidotes. During a military parade on April 15th, North Korea displayed weapons including an intercontinental ballistic missile (ICBM) that could be capable of reaching the U.S. ARS may have just become a larger threat to health than it was just a few weeks ago. [Read more…]